CN101361754A - Use of rare-earth element salt or pharmaceutical composition thereof in preparing medicine for treating or preventing diabetes and adiposis - Google Patents
Use of rare-earth element salt or pharmaceutical composition thereof in preparing medicine for treating or preventing diabetes and adiposis Download PDFInfo
- Publication number
- CN101361754A CN101361754A CN 200710142918 CN200710142918A CN101361754A CN 101361754 A CN101361754 A CN 101361754A CN 200710142918 CN200710142918 CN 200710142918 CN 200710142918 A CN200710142918 A CN 200710142918A CN 101361754 A CN101361754 A CN 101361754A
- Authority
- CN
- China
- Prior art keywords
- earth element
- rare
- acid
- gadolinium
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to an application of rare earth element salts in biological field. The rare earth element salts or composite thereof can promote expression of PC1 and PC2 in islet beta cells and hypothalamus in human bodies, effectively promote secretion of mature insulin, lower level of blood sugar in animal bodies, thus achieving the purpose of curing diabetes; in addition, the rare earth element salts can also promote generation and secretion of alpha-MSH, thus achieving the purpose of curing obesity.
Description
Technical field
The present invention relates to rare-earth element salt or the purposes of its pharmaceutical composition in biological field, thereby refer in particular to that rare-earth element salt or its pharmaceutical composition promote in the pancreatic in vivo and hypothalamus in the expression of PC1, PC2 promote beta cell secretion mature insulin and increase the secretion of hypophysis and hypothalamic alpha-MSH thereby to have the purposes for the treatment of diabetes and obesity.
Background technology
The ionic radius of rare earth element ion is similar to calcium ion, belongs to the hard acid metalloid together, and the geometric configuration of its Coordinative Chemistry behavior and coordination compound etc. are similar, can replace the position of calcium in many Biochemical processes, becomes the agonist of calcium.Replacement afterwards still keeps the character of calcium in some process, but also can produce and the more diverse biochemical properties of calcium, thereby the title of ' super calcium ' is arranged.
Rare earth element enters in the body and will extensively act on aminoacid, has found that the rare earth complexes of amino acid has bactericidal effect.After the eighties, there is the author to utilize the paramagnetic rare-earth ion as the probe research conformation of peptide in solution and the coordination mode of peptide and metal ion, these specific structural informations are for the structure-function relationship of biomacromolecules such as analysing protein and enzyme, and the effect characteristics of understanding rare earth ion and other metal ion (as Ca2+) and biomacromolecule all have important value.In addition, all right and protein of rare earth element, biomacromolecule combinations such as nucleic acid change its conformation and function.
Some rare earth compound has been developed as the medicine of curing the disease.Some rare earth compound has been developed as the medicine of curing the disease.The Dakin solution of a kind of commodity Ceriform by name in 1906 is just sold on the European market, and its main chemical compositions is a potassium ceric sulfate.Sedemesis. has been used as antiemetic in the middle of last century and has been used for clinical.Nineteen eighty-two Britain Martindale pharmacopeia 28 editions is recorded cerous nitrate as the treatment burn medicine.Fox and Monafo etc. find 2.2% cerous nitrate (Ce (NO
3)
36H
2O) and the compound recipe suspension of 1% silver sulfadiazine (AgSD), burn there is better curative effect.
Rare earth compound has important medical value aspect anticoagulation.Be called clinically Trombodym-sulfo group .gamma.-pyridinecarboxylic acid neodymium is the high rare earth compound anticoagulant of a hypotoxicity and anticoagulant.
The sulfosalicylic acid chemical compound of neodymium and mishmetal has the analgesic cooling effect of highly significant, than good with the commonly used analgesic paroxysmal pain medicine aspirin of metering.
Experiment by rabbit and monkey shows, lanthanum chloride can prevent the aorta and the coronary atherosclerosis that are caused by meals.
In addition, the sequestration thing of gadolinium (Gd (DTPA)) be use NMR contrast agent the most widely.
Tolbutamide Gd coordination compound (Gd-D860) is the rare earth compounding of synthetic antidiabetic drug tolbutamide (D860), finds that Gd-D860 has stronger blood sugar reducing function, infers that its mechanism of action is to stimulate the pancreatic uelralante to come glucose level control.Nie Yuxiu etc. give low dosage SmCl to diabetes rat
3(0.05mg/kg body weight/day) can obviously improve the level of serum insulin, blood sugar lowering after 1.5 months.Further the effect of experimental result proof rare earth is because adjusting islet cells secretory function causes.The diabetes that caused at the insulin dysmaturity can not fundamentally reach the purpose of treatment. do not find also that so far a good differentiation pancreatic stem cells of inducing promotes the ripe insulin secretion method that increases of insulin simultaneously.
Gadolinium is promoting the purposes that is used for the treatment of in fat alpha-MSH and the ACTH secretion not see that research report is arranged.
Summary of the invention
Main purpose of the present invention provides rare-earth element salt or its pharmaceutical composition promotes the purposes that prohormone convertase 1 and prohormone convertase 2 are expressed in the medicine in the preparation treatment.
Another purpose of the present invention provides rare-earth element salt or its pharmaceutical composition promotes mature insulin and short melanocyte to stimulate the purposes in the hormone secretion medicine in the preparation treatment.
Another object of the present invention provides rare-earth element salt or the purposes of its pharmaceutical composition in preparation treatment or prevent diabetes and obesity drug.
The inventor has now found that after deliberation, rare-earth element salt can make pancreatic stem cells, beta cell in the pancreas, prohormone convertase 1 (prohormone convertase 1 in the beta cell tumor of In vitro culture, abbreviation PC1), prohormone convertase 2 (prohormone convertase 2, abbreviation PC2) expression raises, and these two kinds of enzymes can impel proinsulin to be cracked into insulin, and the secretion of mature insulin is increased.They are not only at external increase insulin and the C-peptide (micromolecule polypeptide that the C-peptide discharges when being degraded to mature insulin for the proinsulin human, the mensuration of C-peptide is the more special assay method of sophisticated people's pancreatic, because it is not subjected to the interference of the hyclone in the cell culture medium.) secretion, and high fat fed the therapeutical effect that the diabetic mice of inducing generation has blood sugar lowering.In the pancreas of mice, observe increasing of PC1, PC2, and in the serum of mice, observe the reduction of insulin precurosor and the secretion of the mature insulin that increases.
In addition, the inventor finds after deliberation, rare-earth element salt can make the expression of PC1 in the hypothalamus, PC2 raise, these two kinds of enzymes can also impel multiple biological activity propeptide proopiomelanocortin (POMC) enzymolysis to generate thyroliberin (ACTH) and short melanocyte stimulates hormone (alpha-MSH), and hypophysis and hypothalamic alpha-MSH secretion is increased. and alpha-MSH can regulate the food ration of losing weight. and high fat is fed induces obesogenous mice that slimming therapeutical effect is arranged.
Wherein, above-mentioned rare-earth element salt is the acylate or the inorganic acid salt of rare earth element.
Above-mentioned rare earth element includes but not limited to: lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), lutecium (Lu), yttrium (Y), scandium (Sc), preferred rare earth element is lanthanum (La), gadolinium (Gd), lutecium (Lu), most preferably gadolinium (Gd).
Above-mentioned organic acid is citric acid or acetic acid, and described mineral acid is sulphuric acid, hydrochloric acid, hydrobromic acid, Fluohydric acid. or hydroiodic acid.
Further, the preferred chloride of rare-earth element salt, bromide, iodide, the more preferably chloride of rare earth element, most preferably Gadolinium trichloride.
The present invention also provides a kind of rare-earth element salt or the application of its pharmaceutical composition in preparation treatment or prevent diabetes medicine, comprises giving diabetics with rare-earth element salt.Diabetes herein are meant insufficient insulin or do not have the diabetes that insulin produces, as I type and type ii diabetes.
In addition, the present invention also provides a kind of rare-earth element salt or the application of its compositions in preparation treatment or prevention of obesity disease drug, comprises giving the obesity patient with rare-earth element salt.The inventor gives mice that high fat feeds the obesity of inducing generation with rare-earth element salt or its compositions, the body weight gain of finding mice is controlled, the degree of intravital athero and interior fatization all be improved significantly, from experimental data, gadolinium salt is than the better effects if of other rare-earth element salt.
Therefore, the present invention promotes the expression of PC1, PC2 by utilizing rare-earth element salt, thereby promotes pancreatic secretion mature insulin, makes the interior blood glucose of animal body descend, and impel hypophysis and hypothalamic alpha-MSH secretion to increase, thereby reach the purpose of treatment diabetes and obesity.
The specific embodiment
Embodiment 1:
Gadolinium trichloride promotes the PC1 of the beta cell oncocyte of In vitro culture, the expression of PC2, promotes the conversion of insulin precurosor to mature insulin, increases the secretion of mature insulin.
Mice beta cell oncocyte is that NIT-1 is by (after RPMI 1640 (U.S. Hyclone company)+10% hyclone (FBS) cultivation is gone down to posterity, with 5x10
5The density kind of individual cells/well is implanted in 6 orifice plates, plants after 24 hours, and cell attachment is in good condition, and culture fluid is changed to the PRMI1640 culture medium of serum-free, made the cultured cells synchronization in hungry 16 hours after, add following culture medium respectively:
①RPMI?1640+10％FBS
②RPMI?1640+10％FBS+0.1mM?GdCl3
③RPMI?1640+10％FBS+0.2mM?GdCl
3
④RPMI?1640+10％FBS+0.5mM?GdCl
3
⑤RPMI?1640+10％FBS+1.0mM?GdCl
3
6. RPMI 1640+10% hyclone+1.0mM NaCl
Respectively at 37 ℃, CO
2Cultivate in the incubator of concentration 5% after 24 hours, extract whole-cell protein and do Western Blotting experimental analysis, detect the variation of PC1, PC2 expressing quantity.
More than six kinds of albumen samples, setting sample PCI, PC2 expressing quantity 1. be reference " 1 ".Under the identical situation of Tot Prot (β-actin expression unanimity), observe at normal saline and do not change under the situation of PC1, PC2 expressing quantity, along with the GdCl that acts on cell
3The increase of concentration, PC1, PC2 expressing quantity also increase gradually.The results are shown in Table 1:
Table 1.GdCl
3Inducing mouse beta cell oncocyte is the PC1 of NIT-1, the variation of PC2 expressing quantity
| ① | ② | ③ | ④ | ⑤ | ⑥ | |
| PCI | 1.0 | 2.3 | 3.2 | 6.5 | 8.8 | 1.0 |
| PC2 | 1.0 | 2.7 | 2.9 | 3.8 | 4.9 | 1.0 |
Extract each sample RNA simultaneously, under the identical situation of concentration (18s RNA is as confidential reference items), through the mRNA content of Real Time PCR detection PC1, PC2, the result shows: along with the GdCl that acts on cell
3The increase of concentration, the content of the mRNA of PC1, PC2 also increases gradually, shows GdCl
3Stimulated the expression of PC1, PC2 on the transcriptional level.
Table 2.GdCl
3Inducing mouse beta cell oncocyte is the PC1 of NIT-1, the variation of PC2 mRNA
| ① | ② | ③ | ④ | ⑤ | ⑥ | |
| PCI | 1.0 | 9.1 | 24.5 | 60.9 | 97.4 | 1.0 |
| PC2 | 1.0 | 5.6 | 16.2 | 31.3 | 80.0 | 1.0 |
Above condition of culture, culture fluid is removed in suction, measure the interior insulin of born of the same parents and the content of C-peptide, or this cell is carried out sugar stress test, promptly inhale and remove culture fluid, add the RPMI RPMI-1640 that contains glucose 2.5mM in right amount, after 90 minutes, change culture fluid into contain glucose 25mM RPMI RPMI-1640, after 90 minutes, collect culture fluid and cell respectively, measure the difference content of its insulin and C-peptide.The result represents: after rare earth element is induced, mice beta cell oncocyte be insulin in the NIT-1 cell born of the same parents and C-peptide content with all increase to some extent, and sugar stress after, the insulin in the born of the same parents and the release of C-peptide all be improved (table 3, table 4).
Mice beta cell oncocyte was the interior insulin of NIT-1 cell born of the same parents and the content of C-peptide before and after table 3. was induced
| Insulin (μ IU/ml) | C-peptide (pmol/ml) | |
| Before inducing | 20.7 | 15.7 |
| Induce back (0.01mM Gadolinium trichloride) | 43.8 | 24.3 |
| Induce back (0.1mM Gadolinium trichloride) | 86.0 | 38.6 |
| Induce back (1mM Gadolinium trichloride) | 111.2 | 45.4 |
Mice beta cell oncocyte was that NIT-1 cell sugar stress experimental result before and after table 4. was induced
| Insulin content in the cell culture fluid (uIU/ml) | Insulin content (μ IU/ml) in the cell born of the same parents | |
| Before inducing | 21.5 | 20.7 |
| Induce back (0.01mM Gadolinium trichloride) | 43.3 | 43.8 |
| Induce back (0.1mM Gadolinium trichloride) | 85.7 | 86.0 |
| Induce back (1mM Gadolinium trichloride) | 119.5 | 111.2 |
Embodiment 2:
Separation and purification normal mouse islets of langerhans, external through GdCl
3Stimulate the variation of back PC1, PC2 expression
Only choose 6-8 week macrandry ICR/C57 mice 6-10, separate the purification islets of langerhans, with the islets of langerhans In vitro culture that extracts, the separation and purification concrete grammar of mouse islets is as follows:
1. mice overnight fasting (can't help water), the execution of craning one carries out disinfection to skin of abdomen with 75% ethanol.
2. carefully open the abdominal cavity, passivity is separated, and fully exposes gallbladder.Enter duodenal position at common bile duct and carry out ligation with suture.
3. syringe is carefully inserted from the nearly liver end of common bile duct, inject 2～3ml/ mice of collagenase working solution.After treating that pancreas is fully full and expanding, win pancreas fast, insert in the clean centrifuge tube, add the 3ml collagenase.
4. centrifuge tube is put into 37 ℃ of water-baths and digested, jolt frequently, pancreas is fully contacted with collagenase.
5. when treating pancreas digestion, take out, add cold HBSS or PBS immediately fully to jolt mixing, leave standstill on ice to stop digestion in 4 ℃ for fine sand shape (needing about 30 minutes approximately).
6. after treating that Digestive system cools off fully, in 4 ℃, centrifugal 30 seconds of 1000rpm.Abandon supernatant, add cold HBSS or the PBS of 10ml and fully jolt mixing, in 4 ℃, centrifugal 30 seconds of 1000rpm.
7. with the supernatant Ex-all, add 5ml Histopaque1077, fully mixing is a suspension, carefully adds 5mlHBSS or PBS again, is sure not to jolt test tube.4 ℃, centrifugal 20 minutes of 2200rpm is necessary for brakeless and stops.At this moment, liquid is divided into three layers in the visible pipe, with second layer sucking-off, places another clean centrifuge tube, washes 2-3 time repeatedly with HBSS or PBS.
8. in microscopically islets of langerhans is chosen, in (1640+15%FBS), cultivated.Islets of langerhans can be dyeed specifically by dithizone (DTZ), is scarlet.The preparation of collagenase working solution: collagenase V (available from Sigma) is dissolved in the working solution that is made into concentration 1mg/ml among HBSS or the PBS, filtration sterilization, and it is standby to be stored in 4 ℃ of refrigerators.Matching while using is placed and is no more than 2 days as far as possible.
Separation and purification normal mouse islets of langerhans is divided into 3 groups at random, places respectively
①RPMI?1640+15％FBS
②RPMI?1640+15％FBS+1.0mM?GdCl
3
③RPMI?1640+15％FBS+1.0mM?NaCl
In three kinds of culture medium,, cultivate after 24 hours in the incubator of C02 concentration 5%, collect three groups whole protein lysate, detect the difference of three groups of sample P C1, PC2 expressing quantity with Western Blotting method in 37 ℃.Found that, under the identical situation of Tot Prot (GAPDH is as confidential reference items albumen), through GdCl
3Post-stimulatory islets of langerhans PC1, PC2 expressing quantity are all than the high 4-6 of islets of langerhans that does not stimulate doubly.And the islets of langerhans that gives NaCl does not obviously change with the normal islets of langerhans of cultivating.
Extract three groups mRNA simultaneously, detect the mRNA content difference of three groups of sample nucleic acid level PC1, PC2 through the RealTime PCR method.Found that, under the situation of mRNA equivalent (18s RNA is as confidential reference items), through GdCl
3Islets of langerhans PC1, the PC2 that stimulates be do not stimulate islets of langerhans 4-6 doubly.And the islets of langerhans that gives NaCl does not obviously change with the normal islets of langerhans of cultivating.The results are shown in Table 5,6.
The variation of the level of PC1, the PC2 mRNA of mouse islets before and after table 5. is induced
| Before inducing | After inducing | The normal saline contrast | |
| PCI | 1.0 | 4.8 | 1.0 |
| PC2 | 1.0 | 5.1 | 1.0 |
The PC1 of mouse islets, the variation of the proteic level of PC2 before and after table 6. is induced
| Before inducing | After inducing | The normal saline contrast | |
| PCI | 1.0 | 3.3 | 1.0 |
| PC2 | 1.0 | 4.6 | 1.0 |
Embodiment 3:
GdCl
3Therapeutic effect to the diabetic mice of Pax6 gene mutation
There is serious abnormal development in Pax6 homozygous mutation mice, can't survive, so we selects each several of the heterozygous mutant mouse male and female of child-bearing period, copulation production for use.Newborn mice is given birth to normal ablactation in back 21 days, and the male mice of choosing wherein (comprising that genotype is normal and heterozygous mutant) gives the high lipid food nursing.
Fed for 6 weeks from high fat and monitor mouse blood sugars, found that Pax6 mutant mouse majority feeds 10 all future trouble diabetes at high fat.The results are shown in Table 7:
Table 7.Pax6 homozygous mutation mice diabetic mice
Annotate: 1. respectively organize the mice number all greater than 20.
2. high lipid food is provided by Department Of Medicine, Peking University's Animal House, prescription: 21% fat, and 0.15% cholesterol, all the other compositions and normal diet are close.
3. lumbar injection carbohydrate tolerance test IPGTT (Intraperitoneal Glucose Tolerance Testing) is as detecting the index that mice suffers from diabetes.Method is as follows:
1. IPGTT detects 5-6 point survey evening before yesterday mice body weight, and fasting, can't help water, change dressings, the influence of removing residual foodstuff;
2. after fasting 15-16 hour, promptly morning next day the 8-9 point, row IPGTT test.Cut 5-6 μ m from the mouse tail point and get tail blood survey fasting glucose, after the aseptic cotton carrier hemostasis, static 15 minutes;
3. mouse peritoneal is injected 20% glucose, and volume calculates by 10 μ l/g body weight, reduces the stimulation to mice in the operation as far as possible;
4. the injection back was surveyed 30 minutes, and 60 minutes, 120 minutes blood glucose;
5. add the pan feeding piece after experiment is finished.
Glucose for injection: anhydrous glucose is dissolved in sterilized water and is made into 20% glucose, filtration sterilization, and it is standby to be stored in 4 ℃ of refrigerators.Rapid blood sugar instrument and reagent paper are Johnson ﹠ Johnson's product.
Choose Pax6 sudden change diabetic mice, observe GdCl
3Hypoglycemic effect.
Diabetic mice is divided into two groups: first group is GdCl
3The treatment group, second group is physiology saline control group.Treatment is carried out synchronously by two groups, and administering mode is lumbar injection, is administered once in per four days, and the per injection volume calculates by 10 μ l/g body weight, the change of blood sugar of per 16 days capable IPGTT monitoring mices.Treatment GdCl
3Preparation: with solid GdCl
3Powder (available from Sigma) is dissolved in aquesterilisa, is made into the GdCl that concentration is 10mM
3Solution, filtration sterilization, it is standby to be stored in 4 ℃ of refrigerators.Normal saline is injection 0.9% sodium chloride solution, sterilizes, and it is standby to be stored in 4 ℃ of refrigerators.
Found that: after experiment was carried out 32 days, treatment group mouse blood sugar all had reduction, wherein 10% has returned to the euglycemia level, and 70% mice is IGT (impaired glucose tolerance), and control group mice blood glucose obviously raises, and the state of an illness increases the weight of.After experiment is carried out 64 days, be standard with IPGTT120 minute blood glucose, estimate the carbohydrate metabolism level of two groups of mices, treatment group mouse blood sugar reduces 30%-40%, simultaneously control group mice blood sugar increasing 40%-50%.And in the discovery experimentation, the body weight gain of treatment group mice is controlled, and the body weight of control group mice rises always.Find in the process of drawing materials that the degree of intravital athero of treatment group mice and interior fatization is compared with matched group, all be improved significantly.Concrete outcome sees Table 8:
The blood sugar level of experiment diabetic mice before and after table 8. treatment
| Blood sugar concentration (mM) | |
| Before the treatment | 14.9±4.3 |
| GdCl 3The treatment group | 9.7±3.6 |
| The normal saline matched group | 19.5±5.4 |
Annotate:
Below respectively organize the mice number all more than 10.
The present WHO of diabetes diagnosis standard application, the ADA universal standard.
Embodiment 4:
The diabetic mice GdCl of Pax6 sudden change
3The variation of treatment back PC1, PC2
Two groups of mouse islets among the embodiment 3 are separated purification, collect the whole protein lysate of two groups of islets of langerhans, detect the difference of two groups of sample P C1, PC2 expressing quantity with the WesternBlotting method.
Found that under the identical situation of Tot Prot (GAPDH is as confidential reference items albumen), treatment group islets of langerhans PC1, PC2 expressing quantity are than the high 4-6 of matched group times, and albumen is more stable.Extract the RNA of two groups of islets of langerhans, after reverse transcription is cDNA, detect the difference of the mRNA level of two groups of sample P C1, PC2 through the RealTime PCR method.Under the situation of RNA equivalent (18s RNA is as confidential reference items), the mRNA of treatment group islets of langerhans PC1 amount is 5-7 a times of matched group, and the amount of treatment group islets of langerhans PC2 is 70-100 a times of matched group.
The comparison of islets of langerhans form: the mouse islets of separate purifying, in microscopically counting and size relatively, find that the islets of langerhans number of treatment group mice is about more than 5 times of matched group, and volume is obviously greater than matched group, and complete form.
Embodiment 5:
GdCl
3The diabetic mice serum insulin precursor of treatment back Pax6 sudden change and the variation of mature insulin
The manufacture method of diabetic mice and GdCl
3Therapeutic Method with embodiment 3.
The result shows that sugar stimulates GdCl after 2 hours
3The content of mature insulin obviously raises in the treatment group serum, and the control group mice insulin precurosor of normal saline treatment is higher than the treatment group, shows GdCl
3Treatment has promoted the maturation and the secretion of the intravital insulin of diabetic mice, thereby reaches the effect of blood sugar lowering treatment diabetes. concrete outcome sees Table 9.
The serum insulin level of table 9. experiment diabetic mice
| Insulin precurosor content (pM) | Insulin content (pM) | |
| The normal control group | 22.0±0.12 | 151.8±6.39 |
| Diabetic model group | 73.6±2.63 | 130.12±1.00 |
| Diabetes+GdCl 3The treatment group | 20.3±0.58 | 158.4±8.32 |
Embodiment 6:
The citric acid gadolinium promotes the PC1 of the beta cell oncocyte of In vitro culture, the expression of PC2, promotes the conversion of insulin precurosor to mature insulin, increases the secretion of mature insulin.
Experimental technique is with embodiment 1.The result is as follows:
Table 10. citric acid gadolinium inducing mouse beta cell oncocyte is the PC1 of NIT-1, the variation of PC2 expressing quantity
| ① | ② | ③ | ④ | ⑤ | ⑥ | |
| PCI | 1.0 | 2.5 | 3.6 | 7.2 | 7.9 | 1.0 |
| PC2 | 1.0 | 1.9 | 2.6 | 5.8 | 6.3 | 1.0 |
Table 11. citric acid gadolinium inducing mouse beta cell oncocyte is the PC1 of NIT-1, the variation of PC2 mRNA
| ① | ② | ③ | ④ | ⑤ | ⑥ | |
| PCI | 1.0 | 8.2 | 16.5 | 33.9 | 68.2 | 1.0 |
| PC2 | 1.0 | 4.7 | 14.2 | 29.6 | 57.0 | 1.0 |
Mice beta cell oncocyte was the interior insulin of NIT-1 cell born of the same parents and the content of C-peptide before and after table 12. citric acid gadolinium was induced
| Insulin (μ IU/ml) | C-peptide (pmol/ml) | |
| Before inducing | 21.3 | 14.9 |
| Induce back (0.01mM citric acid gadolinium) | 39.9 | 22.8 |
| Induce back (0.1mM citric acid gadolinium) | 79.1 | 33.5 |
| Induce back (1mM citric acid gadolinium) | 105.8 | 42.3 |
Embodiment 7:
Gadolinium is to the treatment of diabetic mice
Experimental technique is with embodiment 3.The result is as follows:
The blood glucose and the serum insulin level of table 13. experiment diabetic mice
| Blood glucose (mM) | Insulin content (μ IU/ml) | |
| Diabetic model group | 15.6±2.74 | 9.12±1.00 |
| Diabetes+gadolinium group | 8.9±1.96 | 16.9±3.64 |
Embodiment 8:
Digadolinium trisulfate is to the treatment of diabetic mice
Experimental technique is with embodiment 3.The result is as follows:
The blood glucose and the serum insulin level of table 14. experiment diabetic mice
| Blood glucose (mM) | Insulin content (μ IU/ml) | |
| Diabetic model group | 15.6±2.74 | 9.12±1.00 |
| Diabetes+Digadolinium trisulfate group | 11.3±3.51 | 14.2±2.23 |
Embodiment 9:
Lanthanum chloride is to the treatment of diabetic mice
Experimental technique is with embodiment 3.The result is as follows:
The blood glucose and the serum insulin level of table 15. experiment diabetic mice
| Blood glucose (mM) | Insulin content (μ IU/ml) | |
| Diabetic model group | 15.6±2.74 | 9.12±1.00 |
| Diabetes+lanthanum chloride group | 12.2±2.12 | 11.9±3.05 |
Embodiment 10:
Lutecium chloride is to the treatment of diabetic mice
Experimental technique is with embodiment 3.The result is as follows:
The blood glucose and the serum insulin level of table 16. experiment diabetic mice
| Blood glucose (mM) | Insulin content (μ IU/ml) | |
| Diabetic model group | 15.6±2.74 | 9.12±1.00 |
| Diabetes+lutecium chloride group | 13.7±1.28 | 11.1±2.66 |
Embodiment 11:
GdCl
3The variation of PC1, PC2 in the obesity mice hypothalamus that the high fat of treatment back Pax6 sudden change is fed
Two groups of mice thalamuses among the embodiment 3 are separated purification, collect the whole protein lysate of two groups of thalamuses, detect the difference of two groups of sample P C1, PC2 expressing quantity with the WesternBlotting method.
Found that under the identical situation of Tot Prot (GAPDH is as confidential reference items albumen), treatment group thalamus PC1, PC2 expressing quantity are than the high 2-3 of matched group times, and albumen is more stable.Extract the RNA of two groups of thalamuses, after reverse transcription is cDNA, detect the difference of the mRNA level of two groups of sample P C1, PC2 through the RealTime PCR method.Under the situation of RNA equivalent (18sRNA is as confidential reference items), the mRNA of treatment group thalamus PC1 amount is 10-12 a times of matched group, and the amount of treatment group islets of langerhans PC2 is 60-80 a times of matched group.
Embodiment 12:
GdCl
3The variation of alpha-MSH and ACTH content in the serum of the obesity mice that the high fat of treatment back Pax6 sudden change is fed
Collect two groups of mice serums among the embodiment 3, detect two groups of sample alpha-MSH and ACTH content with test kit.
Found that alpha-MSH content is higher 3.5 times than matched group in the treatment group mice serum, ACTH content is higher 3.3 times than matched group.
Embodiment 13:
GdCl
3The body weight change of the obesity mice that the high fat of treatment back Pax6 sudden change is fed
The high fat of table 17. is fed the contrast (the treatment precursor is reset to 1) of the treatment front and back body weight of mice
| GdCl 3The treatment group | The normal saline matched group | |
| Before the treatment | 1 | 1 |
| GdCl 3Treated back 16 days | 0.994 | 1.098 |
| GdCl 3Treated back 32 days | 1.030 | 1.137 |
| GdCl 3Treated back 48 days | 1.089 | 1.228 |
| GdCl 3Treated back 64 days | 1.129 | 1.329 |
Embodiment 14:
The citric acid gadolinium, gadolinium, Digadolinium trisulfate, lanthanum chloride, the body weight change of the obesity mice that the high fat of lutecium chloride treatment back Pax6 sudden change is fed
The high fat of table 18. is fed the contrast (the treatment precursor is reset to 1) of the treatment front and back body weight of mice, and treatment time is 64 days
| The normal saline matched group | Citric acid gadolinium treatment group | Digadolinium trisulfate treatment group | Lanthanum chloride treatment group | Lutecium chloride treatment group | |
| Before the treatment | 1 | 1 | 1 | 1 | 1 |
| After the treatment | 1.329 | 1.114 | 1.143 | 1.198 | 1.207 |
In sum, rare-earth element salt can effectively promote the secretion of mature insulin, makes the interior blood glucose of animal body descend, and reaches the effect of treatment diabetes; And can promote generation and the secretion of alpha-MSH, thereby reach the purpose of treatment of obesity.Wherein from experimental data, gadolinium salt is more excellent than other rare earth element effect.
Claims (10)
1. rare-earth element salt or its pharmaceutical composition promote the purposes that prohormone convertase 1 and prohormone convertase 2 are expressed in the medicine in the preparation treatment.
2. rare-earth element salt or its pharmaceutical composition promote mature insulin and short melanocyte to stimulate the purposes in the hormone secretion medicine in the preparation treatment.
3. rare-earth element salt or its pharmaceutical composition purposes in preparation treatment or prevent diabetes and obesity drug.
4. according to the described purposes of claim 1-3, it is characterized in that described rare-earth element salt is the acylate or the inorganic acid salt of rare earth element.
5. purposes according to claim 4 is characterized in that, described rare earth element is: lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), lutecium (Lu), yttrium (Y), scandium (Sc).
6. purposes according to claim 5 is characterized in that, described rare earth element is lanthanum (La), gadolinium (Gd), lutecium (Lu), preferred gadolinium (Gd).
7. purposes according to claim 4 is characterized in that, described organic acid is citric acid or acetic acid, and described mineral acid is sulphuric acid, hydrochloric acid, hydrobromic acid, Fluohydric acid. or hydroiodic acid.
8. purposes according to claim 7 is characterized in that, described rare-earth element salt is the chloride of rare earth element, bromide, iodide.
9. purposes according to claim 8 is characterized in that, described rare-earth element salt is the chloride of rare earth element.
10. purposes according to claim 9 is characterized in that, described rare-earth element salt is a Gadolinium trichloride.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200710142918 CN101361754B (en) | 2007-08-09 | 2007-08-09 | Use of rare-earth element salt or pharmaceutical composition thereof in preparing medicine for treating or preventing diabetes and adiposis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200710142918 CN101361754B (en) | 2007-08-09 | 2007-08-09 | Use of rare-earth element salt or pharmaceutical composition thereof in preparing medicine for treating or preventing diabetes and adiposis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101361754A true CN101361754A (en) | 2009-02-11 |
| CN101361754B CN101361754B (en) | 2013-04-17 |
Family
ID=40388482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200710142918 Expired - Fee Related CN101361754B (en) | 2007-08-09 | 2007-08-09 | Use of rare-earth element salt or pharmaceutical composition thereof in preparing medicine for treating or preventing diabetes and adiposis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101361754B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103224572A (en) * | 2012-01-31 | 2013-07-31 | 岳旺 | Preparation of alginic acid cerium complex and application of alginic acid cerium as antiemetic drugs |
| CN110279683A (en) * | 2019-07-04 | 2019-09-27 | 江苏安唐医药科技有限公司 | Pharmaceutical composition and its application in preparation treatment and prevention diabetes medicament |
| US10842775B2 (en) | 2016-06-03 | 2020-11-24 | The Trustees Of Columbia University In The City Of New York | Methods of treating Prader-Willi syndrome |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1663561A (en) * | 2004-03-05 | 2005-09-07 | 李凌松 | Use of rare earth element salt in preparation of insulin beta cell for treating diabetes |
-
2007
- 2007-08-09 CN CN 200710142918 patent/CN101361754B/en not_active Expired - Fee Related
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103224572A (en) * | 2012-01-31 | 2013-07-31 | 岳旺 | Preparation of alginic acid cerium complex and application of alginic acid cerium as antiemetic drugs |
| US10842775B2 (en) | 2016-06-03 | 2020-11-24 | The Trustees Of Columbia University In The City Of New York | Methods of treating Prader-Willi syndrome |
| US11957656B2 (en) | 2016-06-03 | 2024-04-16 | The Trustees Of Columbia University In The City Of New York | Methods of treating Prader-Willi syndrome |
| CN110279683A (en) * | 2019-07-04 | 2019-09-27 | 江苏安唐医药科技有限公司 | Pharmaceutical composition and its application in preparation treatment and prevention diabetes medicament |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101361754B (en) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6333775B2 (en) | Long-acting formulation of insulin glargine | |
| CN110354255B (en) | Treatment of diabetes by long acting insulin formulations | |
| CN101601646A (en) | Nasal cavity drop of treatment diabetes and preparation method thereof | |
| CN106310281A (en) | Composition for treating diabetes and application thereof | |
| Ngo et al. | Blood naltrexone levels over time following naltrexone implant | |
| CN101361754B (en) | Use of rare-earth element salt or pharmaceutical composition thereof in preparing medicine for treating or preventing diabetes and adiposis | |
| CN101489573B (en) | Methods for treating autoimmune diseases using a TACI-Ig fusion molecule | |
| Yang et al. | Targeting the NLRP3 inflammasome in diabetic nephropathy | |
| Osei et al. | Diabetogenic effect of pentamidine: in vitro and in vivo studies in a patient with malignant insulinoma | |
| CN105853421A (en) | Novel application of FoxO1 selective inhibitor AS1842856 | |
| CN102895364A (en) | Chinese medicinal active ingredient with effect of treating diabetes mellitus | |
| CN108114271A (en) | The pharmaceutical composition of insulin-containing like growth factor -2 and its application | |
| LIPPMAN et al. | Discordant effects of thyrotropin (TSH)-releasing hormone on pre-and posttranslational regulation of TSH biosynthesis in rat pituitary | |
| WO2011116501A1 (en) | Establishment of rhesus monkey model of autoimmunity type 1 diabetes | |
| CN102228700A (en) | Method for constructing insulin resistance animal model | |
| Zhang et al. | Folate stimulation of wound DNA synthesis | |
| Bhattacharyya et al. | SUN-LB112 Efficacy & Safety After Switchover to Remogliflozin in Indian T2DM Patients-a Real World Study | |
| CN116327771B (en) | Combined medicine for treating inflammation and related diseases | |
| CN111249300B (en) | Application of melatonin combined with mecobalamin in treating diabetic wound healing disorder | |
| GB2476789A (en) | Use of thymosin for treatment of type 2 diabetes | |
| Taj et al. | Acquired partial lipodystrophy: Barraquer–Simons syndrome: A rare case report | |
| Guo et al. | Altered nutrition state in the severe multiple trauma patients undergoing adjuvant recombinant human growth hormone nutritional support therapy | |
| Ude et al. | SAT-LB311 Inoperable, Metastatic Pheochromocytoma & Paraganglioma Tumor Size Reduction After Lu-177-dotatate (Lutathera®) Treatment Trial: The Role of Nursing | |
| CN101077414B (en) | Medicine new use for liver hydrolysis-peptide | |
| CN117106024A (en) | Human serum polypeptide AGDMP1 and application thereof in improving insulin resistance |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Li Lingsong Inventor after: Wen Jinhua Inventor before: Li Lingsong |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: LI LINGSONG TO: LI LINGSONG WEN JINHUA |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130417 Termination date: 20130809 |